Kura Oncology Enters Commercial Stage with Strong AML Drug Launch

SAN DIEGO, CA – March 05, 2026 – Kura Oncology has successfully transitioned from a clinical-stage biotech to a commercial enterprise, reporting a strong early launch for its newly approved cancer drug, KOMZIFTI™ (ziftomenib). In its fourth quarter and full-year 2025 financial results, the company revealed that the drug generated $2.1 million in net product revenue within its first five weeks on the market, signaling robust initial demand and efficient commercial execution.

The U.S. Food and Drug Administration (FDA) granted full approval to KOMZIFTI on November 13, 2025, marking a pivotal moment for the company and for patients with a specific, hard-to-treat form of blood cancer. The drug is the first and only once-daily, oral menin inhibitor approved for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have a susceptible NPM1 mutation. This approval addresses a significant unmet need in a patient population with limited effective options.

“We are encouraged by the early launch trajectory of KOMZIFTI and the positive feedback from physicians, pharmacists and payers on its differentiated clinical profile,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology, in a statement. “With a compelling combination of efficacy, safety, compatibility, and simplicity, we believe KOMZIFTI is well positioned to lead in R/R NPM1-mutated AML.”

A New Force in Precision Oncology

The initial commercial performance of KOMZIFTI is bolstered by rapid market access and endorsements from key clinical bodies. Within the first 90 days of its launch, Kura secured favorable coverage policies from approximately 80% of private payers, all aligned with the drug's approved label and without additional restrictions. This swift payer adoption is critical for ensuring patients can access the new therapy without significant delays.

Adding to its momentum, KOMZIFTI was quickly added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines as a Category 2A recommended treatment. This inclusion serves as a powerful endorsement that guides the prescribing habits of oncologists across the United States. The company also highlighted its operational readiness, delivering the product into the distribution channel within five business days of FDA approval, which triggered a substantial $135 million milestone payment from its collaboration partner, Kyowa Kirin.

Further securing the drug's long-term potential, Kura announced the listing of patents for KOMZIFTI in the FDA's Orange Book, which are expected to provide market exclusivity in the U.S. extending up to July 2044. This long patent life provides a durable foundation for the company to maximize the drug's value and reinvest in its growing pipeline.

Changing the Game for AML Patients

The clinical significance of KOMZIFTI cannot be overstated. The NPM1 mutation is one of the most common genetic alterations in AML, occurring in about 30% of patients. While these patients may respond to initial chemotherapy, relapse is common, and outcomes are poor. Until KOMZIFTI, no therapy was specifically approved for this R/R patient subset.

Data from the pivotal KOMET-001 trial, which supported the drug's approval, demonstrated meaningful clinical benefit. In a heavily pretreated population, ziftomenib monotherapy achieved a complete remission (CR) or CR with partial hematologic recovery (CRh) rate of 25%. Critically, for those who responded, the median overall survival was an encouraging 16.4 months. Experts in the field have noted that this single-agent activity is a significant achievement in such a difficult-to-treat leukemia.

While the drug offers new hope, it comes with a boxed warning for Differentiation Syndrome, a serious and potentially fatal complication associated with this class of drugs that requires careful monitoring and management by physicians. However, leading oncologists who have reviewed the data have noted that the safety profile is generally manageable and consistent with previous studies, especially given the high-risk population it serves.

Navigating a Competitive Future with an Expanded Strategy

While KOMZIFTI currently stands alone as the only approved menin inhibitor for NPM1-mutated AML, Kura Oncology is not resting on its initial success. The menin inhibitor class is an active area of development, with competitors like Syndax Pharmaceuticals advancing their own candidate, revumenib, toward a potential approval later this year. This dynamic landscape makes Kura's forward-looking strategy all the more critical.

The company is aggressively pursuing a multi-pronged expansion strategy for ziftomenib, aiming to move it into earlier lines of therapy and new patient populations. Enrollment is underway for the pivotal KOMET-017 Phase 3 trials, which are evaluating ziftomenib in combination with both intensive and non-intensive chemotherapy for newly diagnosed AML patients with NPM1 mutations or KMT2A rearrangements.

Furthermore, Kura is exploring a host of combination therapies to integrate ziftomenib into the broader AML treatment paradigm. The KOMET-007 trial is testing ziftomenib with standard chemotherapy and in a quadruplet combination with the FLT3 inhibitor quizartinib for patients with co-mutations. Meanwhile, the KOMET-008 study is evaluating its use with another FLT3 inhibitor, gilteritinib, in the relapsed setting. Success in these trials could significantly broaden the drug's addressable market, which Kura estimates at up to 50% of all AML patients.

A Strong Balance Sheet Fueling an Ambitious Pipeline

Executing such an ambitious clinical and commercial strategy requires substantial financial resources, and Kura appears well-capitalized to deliver on its goals. The company ended 2025 with $667.2 million in cash, cash equivalents, and short-term investments. Coupled with an anticipated $180 million in future payments from its partnership with Kyowa Kirin, Kura projects a cash runway sufficient to fund operations into the fourth quarter of 2027.

This financial runway is expected to see the company through several key milestones, including the first topline data readout from the pivotal KOMET-017 frontline trial, anticipated in 2028. The company's increased spending, with a fourth-quarter net loss of $81.0 million, reflects the necessary investments in both commercial launch activities and the advancement of its broad research and development pipeline.

Beyond AML, Kura is advancing its precision medicine pipeline into solid tumors. This includes a trial for ziftomenib in combination with imatinib for gastrointestinal stromal tumors (GIST). The company is also developing darlifarnib, a farnesyl transferase inhibitor, in combination with other agents for advanced renal cell carcinoma and KRASG12C-mutated solid tumors, with preliminary data expected in 2026. This diversified approach, which also includes a next-generation menin inhibitor being explored for cardiometabolic diseases like diabetes, underscores Kura's long-term vision to leverage its scientific platforms across a wide range of high-need diseases.